

# Symlin (pramlintide acetate)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications	Quantity Limit
Symlin (pramlintide acetate)	May be subject to quantity limit

## APPROVAL CRITERIA

Requests for Symlin (pramlintide acetate) may be approved for individual who meet the following criteria:

- I. Individual is 18 years of age or older with diagnosis of Type I or Type II Diabetes; **AND**
- II. Individual is taking mealtime insulin therapy and has failed to achieve glucose control; **AND**
- III. Individual's HbA1C is  $\leq 9\%$ .

Symlin may **not** be approved if individual has any of the following:

- I. Poor compliance with current insulin regimen OR self-monitoring of blood glucose;
- II. Individual is receiving drugs that stimulate gastric motility (i.e. metoclopramide)
- III. Individual has a diagnosis of severe gastroparesis
- IV. Individual has hypoglycemia unawareness or recurrent hypoglycemia requiring assistance within the past 6 months

**Note:** Symlin (pramlintide) has a boxed warning for severe hypoglycemia. Symlin use with insulin has been associated with an increased risk of severe hypoglycemia especially in patients with type 1 diabetes. Careful patient selection and education can reduce hypoglycemia risk.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

## Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: January 15, 2019.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.